SCHEMBL4559701

SCHEMBL4559701

CC(=O)c1ccccc1NC(=O)C(=O)N1CCNCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 1/20 0.54
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CNR2 P34972 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
RAB9A P51151 1/20 0.42
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42
PDK4 Q16654 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MT-CO2 P00403 1/20 0.40
F10 P00742 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558440 0.83 NPC1 (0.57) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL4559727 0.81 SMN1; SMN2 (0.52) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL4558906 0.81 CCNC (0.52) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL4559135 0.80 SMN1; SMN2 (0.51) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL4559529 0.80 KMT2A (0.78) ALDH1A1SMN1; SMN2KMT2AL3MBTL1POLB
SCHEMBL4559855 0.78 POLB (0.53) ALDH1A1SMN1; SMN2KMT2AL3MBTL1POLB
SCHEMBL4559491 0.77 TAS1R3 (0.50) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL6857308 0.77 NPC1 (0.57) ALDH1A1SMN1; SMN2KMT2AL3MBTL1POLB
SCHEMBL4559394 0.76 KMT2A (0.57) ALDH1A1KMT2AL3MBTL1POLBKDM4E
SCHEMBL4557548 0.75 SMN1; SMN2 (0.46) ABCC1ALDH1A1SMN1; SMN2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed
EP-1465631-A4 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-03-30 EP disclosed
EP-1465631-A2 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-13 EP disclosed
WO-2003053366-A2 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 ABCC1 1074/4885ALDH1A1 2146/4885SMN1; SMN2 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.